NSCLC
Conditions
Keywords
MRD, potentially resectable NSCLC, stage III
Brief summary
Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recurrence risk of patients. In this study, EGFR/ALK negative potentially resectable Stage III non-small cell lung cancer were enrolled. Baseline tissues, Peripheral blood samples of patients at baseline puncture tissue, after neoadjuvant therapy, after surgery (if any), after adjuvant therapy, and at multiple nodes during follow-up were collected for 1021-MRD analysis through tumor-informed personalized monitoring MRD test kit. This study aim to explore MRD biomarker in patients with potentially resectable stage III non-small cell lung cancer.
Detailed description
In this prospective study, 65 patients with potentially operable non-small cell lung cancer without driving gene EGFR/ALK mutation in stage III were enrolled in this prospective study. peripheral blood samples from multiple nodes after neoadjuvant therapy, postoperative (if any), adjuvant therapy and follow-up were collected and analyzed by high-throughput sequencing in the target region. Patients were enrolled in the study for 1 year, followed up for 2 years, and the study lasted for 3 years. The patients were followed up for 2 years according to the standard diagnosis and treatment path, with a total of 9 times of follow-up, all of which were 3-month follow-up plan of the standard diagnosis and treatment path, and the follow-up examination was conducted in accordance with clinical standards.
Interventions
None listed
Sponsors
Geneplus-Beijing Co. Ltd.
Peking University Cancer Hospital & Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Capable of giving signed informed consent, age ≥ 18 and ≤ 80. 2. patients with stage Ⅲ non-small cell lung cancer confirmed by histology or cytology have potential surgical opportunities. 3. No driving gene EGFR/ALK mutation. 4. PS = 0-1. 5. the treatment process cooperated with the provision of clinicopathological and imaging data needed in the research process, followed up and collected the blood of the clinical efficacy evaluation nodes, and agreed to use the test data for follow-up research and product development.
Exclusion criteria
1. patients suffering from other malignant tumors. 2. patients change the treatment regimen before receiving the specified treatment or before the disease progresses. 3. Patients could not cooperate with the study for follow-up according to the defined clinical follow-up period; 4. Patients were unable to accept or provide imaging and other designated therapeutic evaluation means.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (RECIST) | follow-up time: 2 years | Disease-free survival (RECIST)： the survival time from operation or radiation to recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | follow-up for 2 years | overall survival from the enrollment to death |
| The prediction of recurrence by positive MRD | follow-up for 2 years | Whether the prediction of recurrence by positive MRD is earlier than that confirmed by clinical diagnosis. |
| pCR rate of MRD-negative patient | 2 years | pCR rate of MRD-negative patient |
| Negative MRD rate in pCR patients | follow-up time: 2 years | Negative MRD rate in pCR patients |
| 2-year DFS of ctDNA-negative patients in operation group / inoperable group | follow-up time: 2 years | 2-year DFS of ctDNA-negative patients in operation group / inoperable group |
Countries
China
Contacts
Primary ContactYuyan Wang
Backup ContactHan Yin
Outcome results
None listed